Lipella pharmaceuticals to present phase 2a data for lp-310 in oral lichen planus at 2025 aaom/eaom international meeting

Statistically significant safety and efficacy data from 0.25 mg and 0.50 mg cohorts to be presented presentation scheduled for thursday, may 15, 2025, at 11:36 a.m. pt pittsburgh, may 15, 2025 – prism mediawire – lipella pharmaceuticals inc.
LIPO Ratings Summary
LIPO Quant Ranking